Home / Transcripts / Nufarm Limited (NUF) · November 18, 2025

Nufarm Limited (NUF) Earnings Call Transcript

November 18, 2025

Australian Securities Exchange AU Materials Chemicals earnings 61 min

Earnings Call Speaker Segments

Operator operator
#1

We appreciate everyone being on the line, and we're glad to have you join us for Nufarm Limited's FY '25 Results Conference Call. <<operator_script>> At this point I'll turn the conference over to Mr. Greg Hunt, CEO. Kindly proceed.

Gregory Hunt executive
#2

Thanks very much, and a warm good morning to all of you. It's a pleasure to have you with us for Nufarm's presentation of results for Financial Year '25. With me on the call today are Brendan Ryan, our CFO at Nufarm; Brent Zacharias, who leads Seed Technologies as Group Executive; and Rico Christensen, the Group Executive for Portfolio Solutions. As this morning's announcement makes clear, our CEO <<inaudible>> — I'll go into the transition in greater depth later on in the presentation. As for today's call, though, my remarks will cover the results for financial year '25. Brendan will take you through the financials, and Rico will address priorities for financial year '26 along with the outlook. Before we get into the presentation, please note the disclaimer on Slide 2, especially the language concerning forward-looking statements. Turning to the result: since the half year, we have delivered on the key profitability targets and leverage unwind targets that we set out to the market in August. Crop Protection's performance has pleased us greatly, with an earnings increase of 18% and, importantly, growth in every region. Our review of Seed Technologies is now complete, and the Board has concluded that a reprioritized strategy should deliver the best value for shareholders. During the year we took action to lower cost and capital requirements throughout the Seeds business, and we are well positioned to capture upside from that business going forward.

Gregory Hunt executive
#3

We posted a statutory loss of $165 million. That figure includes $142 million of largely non-cash material items tied to what came out of the Seed Technology review and the wider performance improvement program running across the company. Our confidence is high that the steps we've taken leave the business positioned well for what lies ahead. Net debt came down by $538 million versus the half, and we finished the period at 2.7x leverage. That mirrors the seasonal unwind that is built into our business, along with our capacity to delever via internal discipline and efficiency. We're well placed to produce earnings growth and achieve additional leverage reduction during this financial year, driven by growth in Crop Protection and better performance in Seed Technologies. We expect meaningful positive cash flow generation and a lower CapEx profile to underpin further deleverage at the close of the 2026 financial year. Now I'll walk through a few of the highlights from financial year '25. Within Crop Protection, as I mentioned, we turned in a strong result, with profitability growth across every region and a 140 basis point lift in EBITDA margin. In North America, we posted a record year for profitability in the turf and ornamental segment, and in APAC, a record profit in Asia.

Gregory Hunt executive
#4

Over in Europe, profitability rose 22%, which shows how focused we've been on lifting returns in that business. Within Seed Technologies, the repositioning is moving along well, and that includes lowering our cash costs. We're concentrating on expanding our profitable hybrid seeds operation, and the higher revenue and profitability in South America have us genuinely encouraged. Turning to bioenergy, planted area for carinata went up as market fundamentals kept getting stronger. The market has developed the way we anticipated, with feedstock shortages meeting the demand that the Renewable Energy Directive in Europe and the mandates that followed have created. We've built a long record of creating solutions for farmers through innovation, using a capital-light technology partnership approach. Our near- and medium-term pipeline is very strong, and we've brought multiple product launches to multiple markets throughout our Seed and Crop Protection platforms. Launches of new products in Crop Protection accounted for roughly 15% of financial year '25 revenues. On operating performance, a 100 basis point gross margin improvement has us pleased. Solid internal discipline on working capital and cost helped bring net debt down in the second half.

Gregory Hunt executive
#5

As you're aware, back in May of this year we announced a review of our Seed Technologies business. That review involved a thorough assessment of our strategy, along with the potential for a sale and for bringing in a capital partner. Following a considerable amount of work, the Board has concluded that the outcome expected to deliver the highest value for shareholders is continued ownership under a reprioritized strategy — one in which we focus on growing our hybrids seeds business, on reducing the cash requirements for omega-3, and on expanding our bioenergy business with BP. Actions have already been taken to lower cash costs and capital requirements across the business. Our focus is on continued growth of hybrid seeds in markets where we have established positions and strong growth prospects, particularly South America and Australia. We intend to grow bioenergy, supported by our agreement with BP and by expected demand growth stemming from biofuels mandates. In omega-3, our near-term focus is on supporting customers with the existing inventory and managing to a cash flow-neutral outcome. Over the medium term, we have the opportunity to reposition production to South America, with the aim of lowering our cost of production and improving our competitive position.

Gregory Hunt executive
#6

We’ve got a clear route to create shareholder benefits as we work alongside downstream customers and push toward a lower cost position. Performance across Crop Protection has us genuinely pleased, with underlying EBITDA rising 18%. Our focus was on profitable growth while volumes stayed flat. Both revenue and profit increased, helped by mix and margin. The team also handled inventory management really well, and we’re seeing gains from the performance improvement plan, mainly in Europe. Now turning to the regional Crop Protection businesses. Underlying earnings rose 10% in APAC, a solid outcome given how dry weather in Australia affected things. We achieved record revenue and profitability in Asia, and the margin improvement came from better COGS of goods and product mix. In North America, we increased underlying earnings by 19% over the year, with momentum strengthening in the second half, which was 30% higher than the second half of 2025. That was an excellent result considering the team was navigating some dynamic market conditions related to tariffs and antidumping duties. The turf and ornamental segment had a very good year and delivered a record result, mainly driven by stronger demand in the golf and lawn care sectors.

Gregory Hunt executive
#7

The margin gain came from better COGS and product mix. As I said before, we also enjoyed a strong year in Europe, where underlying EBITDA rose 21%. Margins widened thanks to an improved mix and the benefit improvement program. Results were further helped by more favorable seasonal and market conditions that drove volume growth. The business carries solid momentum, and additional upside should come this year as we keep executing our performance improvement plans. Now let's move to Seed Technologies. We believed it would help to offer greater visibility into the segments. So we have separated our earnings from hybrid seeds and the emerging technologies, which cover bioenergy and omega-3. Hybrid seeds delivered a good performance with EBITDA of $67 million, and the decline in earnings versus the prior period was chiefly due to dry weather in Australia, which hurt canola seed sales. South America sorghum and sunflower came in ahead of the previous year. We have streamlined operations in Europe and North America as we concentrate on the markets that are most attractive and where our positions and growth potential are strongest. In bioenergy, we gained from increased hectares planted and the resulting seed margin. That gain, though, was offset by reduced licensing fees under our agreement with BP.

Gregory Hunt executive
#8

We've witnessed a robust rebound in GHG market values across Europe, and that's pushing up oil demand along with the value outlook for carinata. Omega-3 earnings took a hit from the drop in fish oil prices. Inventory has been carried into the current financial year, and it gives us the ability to serve customers as we work to ship production to South America, where our target is a lower cost of goods. We're making progress toward customer offtake agreements to boost predictability on both volume and price. And as I mentioned earlier, we've substantially cut the cost and capital profile of our omega-3 business. One last thing I want to stress: as a result of our view -- our review, we've shifted the cash requirements of the Seed Technologies business so it becomes more self-funding. I'll now turn it over to Brendan to cover the financials.

Brendan Ryan executive
#9

Thanks, Greg. I'll start by summarizing how we performed in financial year '25. What we're presenting today lines up with the market update we gave back in August. In financial year '25, we achieved solid top line growth, with revenue rising 3% year-on-year. Gross profit was up 7%, and the gross profit margin widened by 1 percentage point to 26.1%, thanks to strong Crop Protection margins and a favorable mix. EBITDA after material items came in as a loss of $74 million. Net financing costs were $101 million, a decrease of 6% year-on-year. The reported statutory loss was $165 million, and 2 significant factors affected it. First, the material items of $142 million, mainly stemming from the Seed Technologies' review — I'll go into more detail on that shortly — and second, $53 million of early-stage losses from emerging platforms, principally omega-3, which relate to the decline in fish oil prices. Underlying EBITDA was $302 million, versus $311 million in the prior year. Importantly, if you exclude emerging platform losses, underlying EBITDA rose 10% year-on-year, which reflects a strong improvement in crop protection profitability and resilient hybrid seeds performance. Now, more detail on the material items. The after-tax impact of material items was $142 million, which is predominantly non-cash, with a financial year '25 cash impact of approximately $30 million.

Brendan Ryan executive
#10

The main driver of material items was $118.7 million tied to asset rationalization and restructuring at Seed Technologies. Within hybrid seeds, we've reduced the scale of our European sunflower business, since the drawn-out and more intense Russia-Ukraine conflict has made that market considerably less appealing. That led us to impair sunflower IP and write down the related seeds inventory, which accounts for most of this material item. This material item also covers pulling back on omega-3 plantings in North America, with plans to shift production into South America so we can reach a more competitive cost of goods sold. That produced a write-down of the surplus omega-3 seed inventory. On top of that, there are redundancy costs tied to the cost-out program and workforce reductions. Disclosed separately, though mainly linked to the seeds review, is $5.4 million in legal and advisory costs. We additionally took $13.4 million in restructuring costs within Crop Protection. Those costs take in redundancy expenses from the cost-out program along with some asset rationalization. For financial year '26, we anticipate clear benefits from the steps taken in financial year '25, including lower capital expenditure, tighter capital allocation and reduced staff and operating costs. Moving now to margin and costs: underlying gross margin rose 80 basis points, and Crop Protection posted a solid 140 basis points of improvement, helped by cost of goods efficiencies and a favorable mix.

Brendan Ryan executive
#11

Operating costs are still a key area of attention for us. Underlying SG&A rose 10% compared with a year earlier, and measured against revenue it was up 140 basis points. That increase reflects inflationary pressure as well as more spending on R&D, marketing and business development to support top-line growth. Going forward, keeping operating costs disciplined is a priority. We expect the full-period benefit of the $50 million cost savings program to broadly offset natural cost inflation in financial year '26. Turning now to the balance sheet. Average net working capital sales came in at 38.2%, an improvement of 440 basis points, placing us firmly inside the 35% to 40% target range under our capital management framework. That gain came mainly from inventory efficiency, helped by a focused program and inventory reductions across all crop-protected regions. Average inventory days improved by 16, while receivables days fell by 4, reflecting strong cash collections during the second half seasonal unwind. Payable days were unchanged, which reinforces that the net working capital progress was largely an inventory story. Working capital management remains a key focus, and we are targeting further improvements in financial year '26. On capital expenditure, it was broadly in line with the prior year. Same as property, plant and equipment focused on health, safety and environmental priorities and plant reliability.

Brendan Ryan executive
#12

When it comes to proper tax intangible CapEx, that continues to generate value for the product pipeline. Our investment in Seed Technologies growth platforms was likewise comparable to the previous year. Looking at financial year '26, our target for CapEx sits under $200 million, which shows disciplined capital allocation. That decrease is going to stem from reduced manufacturing spend after the substantial investment made over recent years. Crop Protection R&D is focusing more on near-term priorities and cutting capital for Seed Technologies in line with the reposition strategy. It's worth pointing out that CapEx during the first half of 2026 should drop considerably versus the prior period, since last year's spend was weighted toward the first half. Turning to free cash flow, it came in at negative $131 million, which reflects a number of key factors. Although net working capital movements, excluding omega-3, were positive, the omega-3 position offset those gains. Outflows related to interest, tax, CapEx, lease and step-up security distributions all fed into the overall cash flow result. Going forward, we're strongly positioned to generate meaningful positive free cash flow in financial year '26, backed by the anticipated continued improvement in working capital efficiency, planned CapEx under $200 million, which reflects disciplined investment, significantly lower cash requirements from omega-3, and expected EBITDA growth year-on-year.

Brendan Ryan executive
#13

On net debt, we saw a reduction of $538 million during the second half of '25, which reflects the usual seasonal unwind and shows strong cash conversion in that half. At year-end, net debt stood at $824 million, and the year-on-year increase was driven partly by unfavorable FX movements and omega-3 inventory. Leverage finished at 2.7x, which is below the guidance we gave in August. Bringing down the average remains a priority, and the actions we outlined earlier support that by delivering positive free cash flow in financial year '26. On funding, gross debt excluding leases came to $1.154 billion at year-end. Liquidity stayed strong, with $345 million of undrawn facilities — consistent with the prior period — and $475 million in cash. Our debt facilities are diversified and flexible, backed by a covenant-light financing structure and a staggered maturity profile. The short-term omega-3 credit facility has been successfully refinanced into a 2-year amortizing loan facility maturing in September 2027. Looking forward, we are well positioned to support the seasonal working capital build. We expect this year's build to be lower. CapEx will be $50 million lower in the first half. Omega-3 cash requirements will be significantly lower, and there is additional benefit from the improvement in earnings. Importantly, Nufarm's capital structure is designed to accommodate seasonal funding demands.

Brendan Ryan executive
#14

For the group's main debt facilities, we don't anticipate any short-term refinancing requirements, apart from the standby liquidity facility—whose extension through November 2027 is at a well-advanced stage—and the ABL facility, which comes due in November 2027. A key point: Nufarm's capital structure is built to handle seasonal swings. To wrap up, Nufarm heads into financial year '26 from a solid profitability base with a strong liquidity position. Profitability in Crop Protection was up in every region, and our hybrid seeds business is producing strong profits. Our funding structure stays flexible, backed by $345 million of undrawn facilities and $475 million in cash at the balance date. In second half 2025, net debt saw the customary seasonal unwind of $538 million. We keep taking steps to cut costs and deleverage. Those efforts should yield additional benefits in financial year '26. We anticipate positive cash flow, with a further expected decrease in net working capital, disciplined capital management with capital expenditure under $200 million, and EBITDA growth. To assist with your models, we're providing the following guidance on a few key items for financial year '26. Depreciation and amortization, circa $225 million; net interest expense, circa $105 million; and the effective tax rate, circa 30%. I'll now hand you back to Greg.

Gregory Hunt executive
#15

Thanks, Brendan. Rico will now walk through the outlook and priorities for the year ahead. Before he does that, though, I'd like to offer a few introductory remarks. As you'll have seen in our ASX announcement, Rico has been named CEO and Managing Director of Nufarm, and he'll begin in that role in the new year. Rico came to Nufarm 4.5 years ago to lead portfolio solutions, and he had already spent more than 2 decades in the industry. He has done an excellent job in that position and brings substantial global experience, having run businesses across the Americas, Europe and Asia before joining Nufarm. I'm looking forward to working alongside Rico over the coming weeks and months to support the transition. I'd also like to take this opportunity to thank our shareholders for their support over the last 10 years. Leading this business has been a fantastic opportunity, and I have great confidence in Nufarm's future under Rico's leadership. Over to you, Rico.

Rico Christensen executive
#16

Thank you, Greg. To begin, I want to express my appreciation to the Board for the confidence they've placed in me by naming me CEO designate of Nufarm, and also to Greg for the backing he has given me during the last 4.5 years with the company. It is an honor to be taking the helm at Nufarm, a wonderful Australian business that I hold in deep regard. Within agriculture, Nufarm's reputation extends well past Australia's own borders. Whenever I speak with growers and channel partners in Brazil, in Canada and Spain and other nations, our brand is immediately recognized and respected. People know us for our solutions and for our commitment to being easy to do business with. We hold leading positions in key geographies and core crops, and in key product segments. Our innovative mindset is well known — finding new approaches to support agriculture as it keeps evolving. I bring over 2 decades of experience in the agricultural sector, having run businesses across Europe, South America, North America and Australia. For the bulk of my career, I was competing with Nufarm. Looking at the company from that outsider's perspective, I truly cannot overstate how valuable our brand is, how valuable our leading positions are and how valuable our relationships are — the relationships built with farmers, channel partners and technology partners across more than 100 years of doing business.

Rico Christensen executive
#17

I hold frequent discussions with partners regarding what we're developing in Crop Protection and Seed. Our reputation and the respect we've earned stem from innovation and the way we collaborate with partners. As a result, what we spend on R&D runs at a fraction of what our competitors spend — multiple times lower. That's how Nufarm operates. Beyond all of that, we have a group of committed, diligent individuals who turn up daily with passion burning in their eyes, eager to deliver better outcomes for Nufarm, for the customers we serve, and for those who hold our shares. Once you combine every element I just listed, the value is enormous, and our rivals look at it with envy. My role, supported by all our staff across the world, is to convert that hard-won standing into robust financial results and returns for our shareholders, and to set Nufarm up for stronger performance across the cycle. That brings me to what I'm focused on for FY '26. To begin, steps are already underway to build genuine discipline around costs and how we deploy capital. We're achieving this via multiple adjustments to our processes, our accountability, and the way we work, which together will generate positive free cash flow to help bring down debt and leverage. We'll take that further by making cost and capital discipline part of our corporate culture through sharper structure, clearer delegations, and better-aligned incentives.

Rico Christensen executive
#18

The goal here isn't merely a single instance of better results — we want this to stay a priority across the years and show up in how we perform throughout the cycle. Second, FY '25 delivered encouraging signals regarding both results and profitability in our Crop Protection business. We intend to extend our leading positions across geographies and crops. Our phenoxy portfolio is a strong illustration, since it holds growth potential that partnerships and market presence can unlock. On that note, our pipeline looks healthy across the short, medium and long term. Paired with a sharper emphasis on launch excellence, we anticipate speeding up the impact of the near-term pipeline. We've likewise made solid strides in enhancing net working capital within Crop Protection, and plans are in motion to achieve additional improvement. Third, the seed review gave us valuable learnings. Above all, we must concentrate our efforts more sharply. We are repositioning our strategy and capital allocation so as to deliver better performance and returns over time. During FY '25 we already acted to cut cash expenditure and capital requirements, especially in omega-3. We anticipate reaping the benefits of those actions in financial year '26. Our hybrid seeds constitute a high-quality, cash-generative business.

Rico Christensen executive
#19

There's distinctive, high-value intellectual property here that we intend to expand across Southern Hemisphere markets. Given the right focus and attention, we can see an obvious path for growth ahead, and that's going to be a priority in FY '26. We're dedicated to expanding upon our strategic partnerships and emerging platforms so as to enhance the annual earnings profile. Moving on to the outlook and how these initiatives give us confidence going into FY '26. We anticipate robust EBITDA growth, assuming normal seasonal and market conditions. Within Crop Protection, we anticipate ongoing EBITDA growth, easing from the 18% growth recorded in financial year '25. In hybrid seeds, we likewise anticipate EBITDA growth, and we're aiming at roughly $30 million of EBITDA improvement across our emerging platforms. We're aiming for leverage of 2.0x by the close of FY '26 versus 2.7x at the close of FY '25. We also anticipate substantial positive free cash flow driven by better earnings, enhancements in net working capital, and a reduction in capital expenditure to under $200 million. For the first half, we anticipate net debt comparable to the prior period, yet with leverage lower than the prior period thanks to better earnings.

Rico Christensen executive
#20

To wrap up, I want to say how eager I am to take the helm at Nufarm. My near-term focus is on delivering FY '26, though I also look forward to discussing with you down the road the longer-term growth plans spanning the whole business. Brent Zacharias is joining Greg, Brendan and me now for Q&A. At this point we'll return the call to the operator.

Operator operator
#21

The operator has just given instructions, and the first person in the queue to ask something is John Purtell from Macquarie.

John Purtell analyst
#22

I have just a couple of questions, if you don't mind. First, regarding the seeds review process, could you give us a bit more detail there — especially around the decision to keep the business, and also how much interest third parties showed in it?

Gregory Hunt executive
#23

Yes. Thank you for that question, John. So, we saw engagement from the market that was broad, with several parties involved, and the review — as I mentioned during our presentation — the review gave us a chance to challenge ourselves on the cost structure, on capital allocation, and on strategic focus. So the review was fairly broad, it was widespread, and it covered the entire strategy. It was not simply about selling the business or bringing in a capital partner. And as we've said, we've reached the conclusion that, in our view, the best value for shareholders will be achieved by executing from that reprioritized, or repositioned, strategy.

John Purtell analyst
#24

And one more question — and Greg, before that, I just wanted to wish you the very best in what's ahead. And thank you for all your assistance through the years. My second question is about what you're observing across the broader ag chem industry. Clearly, the last few years have been difficult. Cost of goods sold appears to have reset, which is positive, but pricing still seems subdued, and markets stay competitive. So I'd just like to hear your thoughts on that.

Gregory Hunt executive
#25

Yes. And John, thank you for the comments. So look, what I'd say is that the overall outlook is positive. Seasonal conditions are generally favorable across all of our markets. Grain pricing is supporting demand for both crop protection and our oil seeds sales. I think the key point here is that active ingredient prices have stabilized. So we've replenished inventory at competitive COGS. And generally speaking, I'd say channel inventories, especially in North America, where they've been a bit stubborn, have normalized. So in terms of 2026, I'd say we'd continue to see some volume improvement in Europe. I would expect APAC to probably be broadly flat versus last year. And in North America, we've seen strong growth in the turf and ornamental business, and that's partly a result of lower spend, particularly in golf and lawn care coming out of COVID. I think a more normalized tariff situation, which seems to have settled down now. The tariff benefits on phenoxies and stable active ingredient pricing, I think those are key drivers for our business in North America. So overall, I'd say, going into '26 in what is a pretty positive environment.

Operator operator
#26

The following question is from William Park at Citi.

William Park analyst
#27

I’d like to ask about the $30 million of earnings recovery that you expect across emerging platform. Looking at your slide right now, you mentioned a $29 million non-cash inventory revaluation charge that you took above the line this year. Is that $30 million essentially the offset to that $29 million? Or have you made other changes across emerging platform that you referred to, such as shifting production from North America to South America? I’m just wondering whether that $30 million recovery would require some improvement in fish oil price or lower costs going forward to help you — something that would effectively contribute to delivering it, please?

Brendan Ryan executive
#28

Yeah, thanks for asking. There are 2 parts — sorry. My apologies. Sorry, the question has 2 parts to it. Yes, as part of the repositioned strategy, we've brought down both the cost and the capital profile of the business. And as you said, the second piece concerns the carrying value of the inventory that we're carrying into the current year and financial year '26, which in effect assumes that $29 million will come through largely reflectable at where fish oil pricing stands today.

Gregory Hunt executive
#29

Brent, would you mind giving us a bit more detail on how fish oil pricing is shaping up?

Brent Zacharias executive
#30

Absolutely, and I believe it's widely recognized at this point that fish oil prices declined from their historic peaks and stayed around the $2,500 to $2,600 range throughout calendar year 2025. The reason for that was really the very large back-to-back quotas, the likes of which hadn't been seen in over 10 years. So when we talk about where we stand heading into 2026 and the $30 million improvement in emerging businesses, that's grounded in our understanding of our inventory position, which reflects fish oil prices as of September, when they were at roughly the $2,600 level. Clearly, then, should fish oil prices strengthen over the course of the year, that would likely lend support to pricing moving higher. One more thing I'd mention is that in recent weeks, the recommended North Atlantic quota came in at 35% below last year. And the Peruvian quota has also been announced at roughly 35% below last year as well. So hopefully that gives you a bit more color, William.

William Park analyst
#31

And if we just stay on omega-3 for a moment, you made a commitment to sort of sell down those inventories, but you were hinting at something like a cash flow neutral result. I'm just curious what you mean by that?

Brendan Ryan executive
#32

Yes. As for reaching a cash-flow-neutral result, the business's lower cost of capital structure is what makes it possible. Precisely when cash flow lands obviously hinges on the moment we sell through the inventory. And clearly, that factors into how optimally we accomplish that across the next 1 to 3 years.

William Park analyst
#33

One final thing I wanted to ask about is this: now that the seed treatment business clearly sits within Crop Protection, how are you thinking internally about that business's growth profile? Does it tend to track the hybrid seeds business — the earnings growth you expect from hybrid seeds? Any additional color on seed treatment would be appreciated.

Brendan Ryan executive
#34

Yeah, on the reclassification—regarding that segment change involving seed treatment, roughly $20 million of FY '25 EBITDA moves from being included in Seed Technologies and Crop Protection. After we reviewed Seed Technologies, we concluded that made sense. From a group standpoint, there's no effect on either the P&L or the balance sheet. And as for how things look going forward, we don't see any meaningful shift, with the business mainly, I'd say, sourced in North America and Europe.

Gregory Hunt executive
#35

And Will, if I could just jump in there — I think it's worth noting that our seed treatment business and our hybrid seeds business aren't directly linked in any way. What seed treatment does is supply chemical applications to the wider seed market as a whole, and not only to our hybrid seeds business.

Operator operator
#36

The next question is from Ramoun Lazar at Jefferies.

Ramoun Lazar analyst
#37

Thanks for joining, Rico and Greg, and I wish you both the very best going forward. I have a couple of questions. First, on Crop Protection, I just want a small clarification regarding the growth drivers. It sounds like there's some volume growth, but are you factoring in further gains in that gross margin profile all the way through '26?

Rico Christensen executive
#38

Yes, that's right. In the past we've discussed how the profile we see coming in from our product launches—the NPIs—generally carries a higher margin than the existing business. We've mentioned that before, and looking ahead it remains true. I'd add as well that over the years to come, based on what we know about the pipeline today, it's fairly consistent that these come in at a higher margin than the existing business, which you'll then see reflected in the overall margin for the business.

Ramoun Lazar analyst
#39

That's quite straightforward. Then I had one question about the emerging platform, omega-3 specifically. What I'm hearing is that you plan to handle the cash needs of that business with tighter control. Could you perhaps discuss, I suppose, how that might affect the potential growth profile of the omega-3 platform? Is there anything further you're able to do that might enhance the cost profile of that business, considering the volatility we've witnessed over the last year or so?

Brendan Ryan executive
#40

Yes. So as part of the review, we've cut the cost and capital profile of the omega-3 business, with the emphasis on selling through the inventory we currently hold to meet customer supply requirements over the next couple of years. We're also focused on how to improve our competitive positioning on cost of goods, and that's planned alongside a shift in the production zone to the Southern Hemisphere. That activity is underway today. We'll keep examining the capital profile and the cost profile, knowing that significant steps have already been taken, and that will remain a focus throughout the financial year '26.

Gregory Hunt executive
#41

There's one more thing I want to mention about the carinata bioenergy business — BP's capital contributions are also helping that platform grow.

Ramoun Lazar analyst
#42

All right, all right. But to return to a breakeven position, would you need to see either additional gains in fish oil pricing or some of this relocation of growing into those lower-cost regions before that happens — before earnings reach breakeven? I mean, do you have any kind of time frame for when you might get back to breakeven? It doesn't sound like '26, obviously, but maybe '27?

Gregory Hunt executive
#43

Okay, so we've stated that no crop will be grown by us during calendar year 2026. We've indicated that we'll begin — and to be clear, this is specifically about omega-3 — we've indicated that planting will start in South America with modest volumes during 2026, then scale up through '27 and '28. Another thing I'd like to remind everyone about is that global deregulation represents a major catalyst — a value catalyst — for this platform. And we continue to believe that achieving it in '27 and '28 remains on track. Regarding the hybrid seeds business, it generates cash, so essentially it self-funds. And as I mentioned, to be clear, with respect to the BP relationship, they keep supporting us through the ramp-up, providing both SG&A and R&D support to speed up growth of that platform. So you're correct — at its core, this is an omega-3 matter.

Operator operator
#44

Jonathan Snape of Bell Potter has the next question.

Jonathan Snape analyst
#45

Alright, since there are 3 different people, I'll pose 3 questions while I have the time. First, let me touch briefly on seeds — I realize you've already covered some of the particulars, but that $30 million gain in the emerging platform appears to really consist of 3 components, if I may frame it that way; clearly, one of them is carinata. I believe you mentioned plantings are higher. I didn't manage to catch whether you stated the amount by which they rose this year, though I'd assume that delivers some sort of earnings upside to Nufarm. The second component in there, it sounds like, is omega-3, and you're planting less of that. So I'd imagine the losses simply from planting less would again be smaller in '26 when the '25 crop is sold, in terms of the metric you brought up — that being the fish oil component. And I think you've made reference to pricing together for '26.

Gregory Hunt executive
#46

No problem, Jonathan. So I did catch the first part of what you asked, about the higher carinata volume and how it affects seed revenue, seed sales, seed margin, and oil — but the second and third questions didn't come through.

Jonathan Snape analyst
#47

Regarding the omega-3 oil pressure and reduced planting, how much does that contribute to the year-on-year reduction in omega-3 loss? Then I'm trying to work out fish oil, because prices at Peruvian and Chilean ports jumped quite a bit last week. And I'm wondering whether you — it doesn't sound like any of that is currently in your thinking. And I believe that's the first reference price since the AMAPE numbers came out. So if that were to hold or continue, that would benefit the sell-through of the inventory, I'd imagine. Is that roughly how I should think about it, but with the latter part probably not in your thinking at this point?

Gregory Hunt executive
#48

Appreciate that, Jonathan. Brent, would you like to take a shot at it?

Brent Zacharias executive
#49

Okay, Jonathan — a few thoughts on fish oil pricing to start. Yes, we've noticed some signs of the spike you mentioned in Peru, but the key thing to keep in mind is that hardly any volume has changed hands so far, until the quotas are actually harvested. So yes, we're paying attention to it. That said, you're correct that our target of a $30 million improvement for emerging platforms is anchored to how fish oil prices stood as of September — roughly $2,600 in the North Atlantic, which is the benchmark we typically monitor and follow, since those sellers supply certified fisheries. So absolutely, you're right. Should we see some upward movement, that would create upside to the $30 million improvement target. It was really anchored around the $2,600 we observed as of September. And just to add...

Jonathan Snape analyst
#50

No, my curiosity was really about the carinata side and how much that adds.

Brent Zacharias executive
#51

Yes. As Greg mentioned in the script, we’re beginning to see some quite solid fundamentals for carinata with the rise in GHG values. Let me add a comment on that. Twelve months ago, the German GHG ticket price stood at $75 per ton of carbon. Right now, as referenced by Argus, it is trading above $250. So that gives us encouragement. And as you pointed out, we did boost our plantings last year, and we will keep scaling further as we move into 2026, which generates seed margin, and with improving GHG fundamentals, it should also expand the oil premiums that we share with BP.

Jonathan Snape analyst
#52

Let me follow up with this — the next question concerns prices for active ingredients. You mentioned they had sort of leveled off, and I believe a few of your competitors said the same thing over the past week. When I look at ex-China factory gate prices on certain actives, they've actually begun to move upward — something like high single-digit gains year-on-year for some of those commodities. So as you think ahead to 2026 in your baseline assumptions, are you assuming a relatively benign backdrop for actives, and consequently for sell-through prices? Or do you build in that upward movement seen over the last 2 or 3 months in actives, and if you do find something, is it a carry on active?

Rico Christensen executive
#53

For budgeting and forecasting over the upcoming years, we definitely rely on the current pricing. But clearly, we're also highly attentive to price changes originating from China. And it really seems—not only when we consider our own momentum in the second half, but also when we look across the industry—that the industry as a whole is starting to emerge from the pricing slump we've experienced over the last couple of years. So our hope is that this continues in FY '26.

Jonathan Snape analyst
#54

And look, my final question, as usual, concerns the balance sheet. Utilization of the off-balance sheet facility fell fairly significantly compared with a year earlier. It appears you moved $100 million from off to on, which clearly indicates your operating cash flow is probably somewhat stronger. But if I'm reading it correctly, I believe that is the lowest usage of the off-balance sheet facilities by Nufarm that I can locate. Is there some specific reason you are drawing on those facilities considerably less than in the past? Is it aged stock? Is it something else? It simply looks like an unusually low figure.

Brendan Ryan executive
#55

No, that's not the case. So Jonathan, regarding supplier financing — just that single facility — the balance stood at $26 million on the balance date. The reason it's lower is mainly tied to the arbitrage, I suppose, purely on interest rates, especially the gap with Chinese rates. And just to underline the point, if you check our payables days, they've stayed flat. So there's no trade-off, I'd say, between terms of trade and debt.

Jonathan Snape analyst
#56

Right, understood. That said, if you applied those at levels nearer the historical average, then clearly the debt would shift off your own balance sheet. So really it comes down to an interest rate arbitrage play — nothing beyond that, correct?

Brendan Ryan executive
#57

Yeah, that’s right.

Operator operator
#58

Our following question is from Owen Birrell of RBC.

Owen Birrell analyst
#59

To start with my first question, again about omega-3. I was hoping you could give me a clearer picture of where your omega-3 oil inventory stands right now. I'd like to understand how much oil was actually produced during '25 and, on that basis, what carryover inventory you're taking into '26. And just to follow up on what you mentioned about no crop being grown in '26, does that mean no oil at all will be generated in '26?

Brendan Ryan executive
#60

Yes. Thanks for that question, Owen. To clarify where we stand on omega-3 inventory, I won't frame it in metric tons, since that's fairly commercially sensitive. What we do have, though, is inventory carried over into '26 from last year's crop, and it's been valued against current North Atlantic fish oil pricing, which someone described as a $29 million non-cash revaluation. So that's essentially a benefit flowing through into the sales profile in financial year '26. As for the new crop, there's a legacy crop stemming from the FY '25 plantings. We're building in that some revaluation will occur on that crop relative to where fish oil pricing might move going forward. So that's a factor in it. And then, I suppose, broadly speaking, the emphasis is on managing that inventory so as to optimize the cash position we gain from it. That runs alongside managing what our customers require in terms of demand.

Owen Birrell analyst
#61

I realize there was a write-down of $29 million on that inventory position, effectively. But could you help us understand — what is the value of that inventory on your books at present, after that write-down? Roughly how much is it?

Brendan Ryan executive
#62

Honestly, most of the worth tied to that omega-3 facility is likely reflected fairly closely in what the accounts show. So we're talking roughly — my rough estimate is around $100 million, and that's quite near the mark.

Owen Birrell analyst
#63

All right, and my second question is just about the bioenergy platform. You spoke at some length about that new capital-light model, roughly speaking. I'm just curious whether you could give us a feel — functionally or operationally, I suppose — for how that model differs from what you were doing before?

Brendan Ryan executive
#64

There's been no change to the model before now. So three years into the agreement, the model remains the same. From where we sit, it's capital-light, since we carry no balance sheet. That means no inventory lands on our balance sheet, and on top of that, via the partnership, a portion of the supporting costs and capital requirements gets co-funded.

Owen Birrell analyst
#65

So in the past, you were carrying that inventory on your balance sheet? Is that the way I should interpret that?

Brendan Ryan executive
#66

No. Previously, we weren’t putting any inventory on the balance sheet. Apart from the carinata seeds themselves, there’s no oil—neither carinata oil nor biofuel oil—carried on our balance sheet.

Owen Birrell analyst
#67

Okay, but it sounds like the capital-light part is really that BP is the one putting in the capital rather than you yourselves? Is that where the difference lies?

Brendan Ryan executive
#68

The funding for this is shared between BP and us.

Owen Birrell analyst
#69

All right. I’m simply attempting to get clear on what is genuinely different. What has actually changed? You keep referring to a capital-light model, yet it does not sound as though anything has truly changed.

Brendan Ryan executive
#70

There's no difference from before. I'm simply pointing out that this is a capital-light model.

Operator operator
#71

Scott Ryall of Rimor Equity Research has the next question.

Scott Ryall analyst
#72

My first question has to do with Slide 13 and the discussion of R&D spending. I just want to confirm that I heard Brendan right that, generally speaking, R&D expenditure is expected to keep growing. Did I get that correct? And if that's the case, I suppose I'm looking at the material items -- the prior slide. We've impaired some intellectual property on sunflower and canola. And I'm just wondering, and this question holds no matter what the R&D outlook is. But how do you make sure you're getting real value for money? And how are you making certain that you learn from whatever went wrong with that intellectual property? And how does that fit into your reprioritization, please?

Brendan Ryan executive
#73

Thanks for asking that. To be clear about R&D: spending as we move into financial year '26 will sit below the level we had in financial year '25, and the main reason is our near-term emphasis on the research and development pipeline. Sorry, could you remind me what the second part of your question was?

Scott Ryall analyst
#74

On the R&D side, and just to make sure you aren't — that future material items of yours don't involve writing off intellectual property, which presumably is where that R&D spending has ended up. How does that fit into the reprioritization, if you could?

Brendan Ryan executive
#75

Yes, thanks for that. Regarding material items, the material item tied to sunflower stems from the situation—or rather the conflict—unfolding in Ukraine and Russia. It has proven far longer-lasting and more serious than our original expectations. And since that represents a major sunflower market, this is what drove the impairment concerning the sunflower IP. More broadly, when it comes to managing the benefit derived from our R&D investments, we follow a rigorous process to identify the research and development product line that delivers, I suppose, a balance across both the short term and the medium term, paired with a disciplined approach to stage gating and review as we monitor progress on delivering those benefits. I might hand over to Rico, who may wish to add a few further remarks on that point.

Rico Christensen executive
#76

Absolutely. We do anticipate that R&D expense will come down in FY '26 relative to FY '25. That reflects a few of the factors Brendan brought up, such as greater efficiency in stage gate processes and similar areas, and it also reflects the fact that in '25 we had certain one-offs in R&D cost that we disclosed through various press releases regarding agreements with various partners. Once again, those are capital-light models relative to what other companies are doing on R&D. So broadly speaking, we spend considerably less on R&D than our competitors do, thanks to those partnerships we have.

Scott Ryall analyst
#77

Okay. All right. And Rico, my final question is just for you. I’m sorry about the football results overnight, by the way. So you’ve been at Nufarm for over 3 years now. I suppose I’m just wondering, how do you think Nufarm’s position will shift over the next 3 to 5 years compared with what you’ve seen — how the position has changed across the last 3? What do you really believe will be the change in direction for the company, please?

Rico Christensen executive
#78

That's a fair question, and I touched on part of it when I went through the priorities and the outlook. And I think...

Scott Ryall analyst
#79

Was that only for a single year, correct?

Rico Christensen executive
#80

Yes, absolutely. So, as I mentioned in my remarks, the near-term emphasis really centers on discipline around capital and cash. We aim to bring our leverage down, as we've said. Yet at the same time, clearly, we must also address tomorrow's growth at Nufarm, and we keep doing so via our R&D investments in both seeds and cost protection, where we hold a robust near-, medium-, and long-term pipeline. And I think, as we discussed earlier, you can see the effect of our new product launches throughout the business in Crop Protection. We've stated broadly that it's about 15% of revenue. But actually, it's somewhat higher when we consider gross margin. And what you'll observe over time is that as those new products enter the portfolio, they will continue to enhance our gross margin profile and, consequently, the company's earnings as well.

Operator operator
#81

That brings us to the end of the question-and-answer session. I'll return the floor to Rico Christensen now for some closing comments. Rico, please proceed.

Rico Christensen executive
#82

Yes, thank you. I wanted to close by expressing appreciation for joining us. I’m looking forward to reconnecting with a lot of you in the next few days. That brings this call to an end. Thanks.

Operator operator
#83

That brings today's conference to a close. Thanks for joining us. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nufarm Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.